Severe Sore Throat and Fatigue Mark Rise of New PJ.2.1 Covid Strain
Understanding the PJ.2.1 Variant and Its Global Spread
First documented in Ontario, Canada in May 2026, the PJ.2.1 variant of SARS-CoV-2 has drawn international attention after spreading across multiple regions, including the United States, Spain, France, Israel, Singapore, Australia, and New Zealand. Public Health Ontario genomic surveillance data shows the variant grew to account for 25.2 per cent of sequenced samples between September 20 and October 17, 2026, rising from 16.9 per cent in the prior four-week period.
Unlike strains that accumulate mutations gradually over time, PJ.2.1 emerged with multiple genetic changes at once. Laboratory research published as a preprint on October 8, 2026, by scientists at the German Primate Center and Hannover Medical School found that the variant’s spike protein binds more effectively to human ACE2 receptors. While this enhanced binding capacity may give the strain a competitive edge in infecting human cells, health institutions stress that laboratory cell interaction does not translate directly into worse clinical outcomes. The World Health Organisation is closely monitoring the strain, and available data shows no evidence that PJ.2.1 leads to more severe illness, higher hospitalisation rates, or increased mortality compared to previous variants.
Key Symptoms and Diagnostic Requirements
Symptoms reported with PJ.2.1 closely mirror standard respiratory infections like influenza or the common cold, but specific clinical indicators stand out. Russian infectious disease specialist and virologist Elena Malinnikova highlighted severe sore throat and prolonged fatigue as two features that particularly mark this strain. Patients may experience an unusually intense throat infection alongside tiredness that persists even after initial symptoms improve.
Standard physical symptoms alone cannot verify whether a person has contracted PJ.2.1. Standard Covid-19 testing is required to confirm the presence of the virus, while specialized genomic sequencing is necessary to identify the exact PJ.2.1 strain. Surveillance tracking published on November 5, 2026, by Hong Kong’s Centre for Health Protection confirmed the presence of the wider JN.1 lineage under which PJ.2.1 is tracked.
